Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study

Lancet Neurology

Volumn 5, Issue 9, 2006, Pages 749-754

  O'Donnell, Martin ^a   Oczkowski, Wes ^a   Fang, Jiming ^b   Kearon, Clive ^a   Silva, Jaime ^a   Bradley, Christine ^a   Guyatt, Gordon ^a   Gould, Linda ^c   D'Uva, Cami ^c   Kapral, Moira ^d   Silver, Frank ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ARTICLE; BRAIN DEGENERATION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL CLASSIFICATION; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DEPENDENT PERSONALITY DISORDER; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANKIN SCALE; RATING SCALE; REGISTER; RISK REDUCTION; STROKE; STROKE PATIENT; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; ONTARIO; PATIENT ADMISSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 33746954539     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70536-1     Document Type: Article

References (19)

1. Singer D., Albers G., Dalen J., et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 429S-456S
2. Hart R., Benavente O., McBride R., and Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
4. Hylek E., Go A., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 (2003) 1019-1026
5. Albers G., Amarenco P., Easton J., Sacco R., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 suppl (2004) 483S-512S
6. Tu J., Willison D., Silver F., et al. N Engl J Med 350 (2004) 1414-1421
7. Kapral M., Silver F., Richards J., et al. Registry of the Canadian Stroke Network progress report 2001-2005 (2005), Institute of Evaluative Sciences, Toronto
8. Adams H., Bendixen B., Kappelle L., et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 24 (1993) 35-41
9. Bamford J., Sandercock P., Dennis M., Burn J., and Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337 (1991) 1521-1526
10. Cote R., Battista R., Wolfson C., Boucher J., Adam J., and Hachinski V. The Canadian neurological scale: validation and reliability assessment. Neurology 39 (1989) 639-643
11. Bonita R., and Beaglehole R. Modification of Rankin scale: recovery of motor function after stroke. Stroke 19 (1988) 1497-1500
12. Muir K., Weir C., Murray G., Povey C., and Lees K. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 27 (1996) 1817-1820
13. Laloux P., Richelle F., Jamart J., DeCoster P., and Laterre C. Comparative correlations of HMPAO SPECT indices, neurological score, and stroke subtypes with clinical outcome in acute carotid infarcts. Stroke 26 (1995) 816-821
14. Evans A., Perez I., Yu G., and Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke 32 (2001) 2828-2832
15. Hart R., Pearce L., Miller V., et al. Cardioembolic vs noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 10 (2000) 39-43
16. Timsit S., Sacco R., Mohr J., et al. Brain infarction severity differs according to cardiac or arterial source. Neurology 43 (1993) 728-733
17. Helgason C. Cardioembolic stroke topography and pathogenesis. Cerebrovasc Brain Metab Rev 4 (1992) 28-58
18. O'Donnell M., and Weitz J. Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation. Am J Manag Care 10 3 suppl (2004) S72-S82
19. Active Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912